Gary Scott Beasley

Dr. Gary Scott Beasley

Le Bonheur Children's Hospital
+2
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
RKRichard Kirk
Richard Kirk
ADAnne I. Dipchand
Anne I. Dipchand
RDRyan R. Davies
Ryan R. Davies
OMOliver Miera
Oliver Miera
GCGretchen Chapman
Gretchen Chapman
WZWarren A. Zuckerman
Warren A. Zuckerman

28 April 2017 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
TMTimothy M. Markman
Timothy M. Markman
KRKathryn Ruble
Kathryn Ruble
DLDavid Loeb
David Loeb
ACAllen Chen
Allen Chen
YZYiyi Zhang
Yiyi Zhang
SNSaman Nazarian
Saman Nazarian

28 April 2021 in Frontiers in Genetics
Verified
Journal Article
Open access
Hugo R. MartinezHugo R. Martinez
Hugo R. Martinez
Gary Scott BeasleyGary Scott Beasley
Gary Scott Beasley
NMNoah Miller
Noah Miller
JGJason F. Goldberg
Jason F. Goldberg
JJJohn L. Jefferies
John L. Jefferies
Cardiomyopathies (CMs) encompass a heterogeneous group of structural and functional abnormalities of the myocardium. The phenotypic characteristics of these myocardial diseases range from silent to symptomatic heart failure, to sudden cardiac death due to malignant tachycardias. These diseases represent a leading cause of cardiovascular morbidity, cardiac transplantation, and death. Since the discovery of the first locus associated with hypertrophic cardiomyopathy 30 years ago, multiple loci and molecular mechanisms have been associated with these cardiomyopathy phenotypes. Conversely, the disparity between the ever-growing landscape of cardiovascular genetics and the lack of awareness in this field noticeably demonstrates the necessity to update training curricula and educational pathways. This review summarizes the current understanding of heritable CMs, including the most common pathogenic gene variants associated with the morpho-functional types of cardiomyopathies: dilated, hypertrophic, arrhythmogenic, non-compaction, and restrictive. Increased understanding of the genetic/phenotypic associations of these heritable diseases would facilitate risk stratification to leveraging appropriate surveillance and management, and it would additionally provide identification of family members at risk of avoidable cardiovascular morbidity and mortality.

17 May 2022 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JGJustin Godown
Justin Godown
DFDarlene Fountain
Darlene Fountain
NBNeha Bansal
Neha Bansal
RARebecca Ameduri
Rebecca Ameduri
SASusan Anderson
Susan Anderson
SHSeth A. Hollander
Seth A. Hollander
Background: Children with Down syndrome (DS) have a high risk of cardiac disease that may prompt consideration for heart transplantation (HTx). However, transplantation in patients with DS is rarely reported. This project aimed to collect and describe waitlist and post– HTx outcomes in children with DS. Methods and Results: This is a retrospective case series of children with DS listed for HTx. Pediatric HTx centers were identified by their participation in 2 international registries with centers reporting HTx in a patient with DS providing detailed demographic, medical, surgical, and posttransplant outcome data for analysis. A total of 26 patients with DS were listed for HTx from 1992 to 2020 (median age, 8.5 years; 46% male). High‐risk or failed repair of congenital heart disease was the most common indication for transplant (N=18, 69%). A total of 23 (88%) patients survived to transplant. All transplanted patients survived to hospital discharge with a median posttransplant length of stay of 22 days. At a median posttransplant follow‐up of 2.8 years, 20 (87%) patients were alive, 2 (9%) developed posttransplant lymphoproliferative disorder, and 8 (35%) were hospitalized for infection within the first year. Waitlist and posttransplant outcomes were similar in patients with and without DS ( P =non‐significant for all). Conclusions: Waitlist and post‐HTx outcomes in children with DS selected for transplant listing are comparable to pediatric HTx recipients overall. Given acceptable outcomes, the presence of DS alone should not be considered an absolute contraindication to HTx.


1 February 2020 in ASAIO Journal
Verified
Journal Article
Closed access
Gary Scott BeasleyGary Scott Beasley
Gary Scott Beasley
KAKiona Allen
Kiona Allen
EPElfride Pahl
Elfride Pahl
LJLindsay Jackson
Lindsay Jackson
OEOsama Eltayeb
Osama Eltayeb
PTPhilip Thrush
Philip Thrush
Pediatric heart transplant candidates have the highest wait-list mortality of all organ candidates. Mechanical circulatory support has improved survival for many patients awaiting transplant. Biventricular mechanical circulatory support remains a particular challenge for pediatric patients. We present the smallest patient (body surface area 0.9 m2) to date to receive the 50 cc SynCardia Total Artificial Heart, supported for 278 days before successful heart transplant.